SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

SLAP is trending as community members rally around the project's real-world partnerships, including a sponsored MMA fighter. The community emphasizes their daily grind and commitment to building a recognizable brand within sports culture, attracting attention and engagement. Bullish sentiment and frequent mentions across social media platforms contribute to its current momentum.

What makes MOG an absolute game-changer is our relentless dedication to memes and viral brilliance! We don't settle for mediocrity; we plunge into the realm of sheer awesomeness! Our community is a powerhouse of meme warriors, unleashing an unstoppable onslaught of viral memes that'll leave you in awe and stitches!  We're not here to play games; we're here to dominate! MOG is all about pushing the boundaries, smashing through barriers, and leaving our competitors eating our dust! Our passion for humor burns like an inferno, and we won't rest until the entire internet bows down to our meme supremacy!  And our community? It's a brotherhood, an unyielding powerhouse of support and camaraderie! When you're part of MOG, you're part of an unstoppable force, a family forged by the fire of meme revolution!  So, if you're ready to be part of the most intense, mind-bending memecoin movement ever conceived, then buckle up, strap in, and brace yourself! MOG is here to claim the throne, and we're taking no prisoners! Get ready to witness meme history in the making!

 MOG Coin

MOG Coin is trending amidst community excitement about potential gains, with some suggesting it could mirror past rallies. Bullish investors are actively buying and holding, while others debate whether it's a "scam" or a promising meme coin. Some traders are also pointing to a potential Robinhood listing on the horizon.

AABG Token

AABBG is trending as investors discuss its potential, production updates, and recurring dividends, while others express concerns about timelines and dilution. Community members debate market manipulation and the company's execution, with some calling for patience and others demanding more transparency. Sentiment is mixed as shareholders await updates on financials, buybacks, and the AABB wallet.

BlackRock Institutional Trust Company N.A. - iShares China Large-Cap ETF

iShares China Large-Cap ETF

The iShares China Large-Cap ETF ($FXI) is trending amid U.S.-China trade tensions and speculation around potential tariff adjustments, influencing investor sentiment. Community discussions revolve around the ETF's technical uptrend, potential resistance levels, and the broader implications of trade dynamics on Chinese equities. Some investors express bullish sentiment, citing discounted valuations, while others remain cautious due to geopolitical risks and the potential for renewed trade conflicts.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

VELO is trending amid discussions of its strategic partnerships, particularly within the defense and aerospace sectors, with community members highlighting potential growth catalysts. The company's collaborations with iRocket and its focus on U.S.-based manufacturing are sparking interest. Discussions also include the company's financial health, potential for profitability, and technical analysis of the stock.

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Protagonist Therapeutics Inc

Protagonist Therapeutics ( $PTGX ) is trending due to positive Phase 2b trial results of Icotrokinra in ulcerative colitis, fueling speculation of a potential buyout by Johnson & Johnson ( $JNJ ). The community is actively discussing potential deal prices and the strategic fit for $JNJ , while analysts are raising price targets. Some traders are wary of overvaluation and potential pullbacks following the surge.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer (ICP) is trending as the community discusses its potential to decentralize the internet and challenge cloud providers, drawing comparisons to Bitcoin's impact on traditional finance.  The launch of Caffeine AI is a key catalyst, though some express concerns over adoption and price movement, while others point to growing network usage and Bitcoin integration as bullish signals. Community debates include its long-term potential, criticisms of its tokenomics, and whether it can achieve mainstream adoption.

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

DASH is experiencing renewed interest, potentially fueled by comparisons to ZEC and discussions around privacy coins. The community is actively debating its potential for significant gains, with some suggesting it could mirror ZEC's performance or even reach new highs during the next bull run. Some users also mentioned potential utility with DoorDash.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance ($PSKY) is trending as investors discuss a potential acquisition of Warner Bros. Discovery ($WBD), with many believing a deal is inevitable despite $WBD's rejection of previous offers. Community members are debating the fairness of proposed deal terms and the potential for a bidding war, while also speculating on the impact of the new UFC streaming deal and cost-cutting measures on the stock's future performance.

BlackRock ESG Capital Allocation Term Trust

BlackRock ESG Capital Allocatin Trm Trst

ECAT is trending due to its high dividend yield, with investors actively discussing its sustainability and comparing it to similar high-yield investments. Recent insider buying and news of BlackRock increasing its position are adding to the positive sentiment. However, some community members express concerns about potential distribution cuts and shorting opportunities.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Should You Buy?

Protagonist Therapeutics (PTGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report?

Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

H.C. Wainwright on Tuesday raised its price target on MannKind to $11 from $9 and reiterated its buy rating on the shares, following positive late-stage study results from partner United Therapeutics for its Tyvaso Inhalation Solution.The brokerage firm said the positive data removes “a significant overhang” on MannKind shares and supports a re-rating of the stock toward intrinsic value, with added upside from royalties and cash flows tied to Tyvaso.The call comes after United Therapeutics said Tuesday that its phase 3 TETON-2 trial showed nebulized Tyvaso improved lung function in idiopathic pulmonary fibrosis patients versus placebo in a dose-dependent manner, meeting the trial's primary endpoint.&nbsp;Over 52 weeks, patients on Tyvaso saw lung capacity improve by 95.6 milliliters compared with placebo, a result the company said was highly statistically significant.&nbsp;Benefits were observed across patient subgroups, and significant gains were also reported in quality of life and other secondary measures. The treatment was well-tolerated with no new safety signals.United Therapeutics said it plans to meet with the U.S. Food and Drug Administration before the end of the year to discuss adding IPF to Tyvaso’s label, with additional data from the ongoing TETON-1 study expected in the first half of 2026.Last week, MannKind said that United Therapeutics had exercised an option under their 2018 license and collaboration agreement to&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mannkind-united-therapeutics-expand-agreement-to-develop-second-investigational-molecule-together/chsURMTRdkC">develop a second dry powder inhalation therapy</a>. The partnership previously produced Tyvaso DPI, the first FDA-approved dry powder inhalation treatment for pulmonary hypertension, cleared in 2022.MannKind will use its Technosphere platform to formulate a new investigational molecule, while United Therapeutics will conduct preclinical and clinical testing. MannKind will receive $5 million upfront, up to $35 million in milestone payments, and a 10% royalty on sales if the therapy reaches market.&nbsp;On Stocktwits, retail sentiment for both MannKind and United Therapeutics was ‘extremely bullish’ amid ‘extremely high’ message volume.One user speculated that United Therapeutics’ growing ties to MannKind reduce the likelihood of a buyout by another large pharmaceutical company, saying they expect a 13G filing showing a bigger ownership stake.&nbsp;<stembedurl>https://stocktwits.com/Hard2beLong/message/627299899</stembedurl>Another user questioned whether it made more sense for United Therapeutics to continue paying MannKind a 10% royalty stream each year rather than pursue a full acquisition.<stembedurl>https://stocktwits.com/Lazarus2024/message/627294687</stembedurl>While&nbsp;<a href="https://stocktwits.com/symbol/MNKD">MannKind’s stock</a> has declined 10.7% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/UTHR">United Therapeutics’ stock</a> has risen 14.7% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

H.C. Wainwright on Tuesday raised its price target on MannKind (MNKD) to $11 from $9 and reiterated its buy rating on the shares. (Photo credit: Getty Images)

MannKind Lands A Price-Target Hike After Partner United Therapeutics Reports Strong Lung Drug Trial Results 

United Therapeutics plans to meet with the U.S. FDA before the end of the year to discuss adding idiopathic pulmonary fibrosis to Tyvaso’s label.

Equity

MannKind Corporation (MNKD) on Wednesday said that it will formulate a dry powder inhalation therapy, and United Therapeutics (UTHR) will conduct preclinical and clinical development under an expanded agreement.The two companies entered into a licence and collaboration agreement in 2018. The agreement led to the US Food and Drug Administration’s approval of Tyvaso DPI in May 2022 and included an option for United Therapeutics to expand the license to include additional active ingredients. Tyvaso DPI was the first FDA-approved dry powder inhalation treatment for pulmonary hypertension.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MNKD">MNKD</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels. Shares of MNKD traded 5% higher in the pre-market session at the time of writing.Meanwhile, retail sentiment around <a href="https://stocktwits.com/symbol/UTHR">UTHR</a> stayed within ‘neutral’ territory, coupled with ‘low’ levels of retail chatter.MannKind CEO Michael Castagna <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/08/27/3139981/29517/en/MannKind-Announces-Expansion-of-United-Therapeutics-Collaboration-for-Second-Inhaled-Therapy.html">said</a> that this next step in the collaboration between the two companies strengthens the existing partnership and the versatility of its dry powder formulations.The company said that it will receive an upfront payment of $5 million under the expanded agreement. It is also eligible to receive up to $35 million milestone payments and 10% royalties on net sales of resulting products.Formulation and development activities for the new investigational molecule will begin immediately, the company said. It will be formulated using MannKind’s proprietary Technosphere inhalation technology.While MNKD stock is down by 37% this year, UTHR stock is down by 12%.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ford-recalls-nearly-356000-vehicles-in-us/chsUG1SRdkx">Ford Issues Nearly 356,000 Vehicles Recall In U.S., But Retail Investors Spot Emerging Catalysts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

MannKind, United Therapeutics Expand Agreement To Develop A Second Investigational Molecule Together

The 2018 agreement between the companies led to US FDA approval of Tyvaso DPI in May 2022 and included an option for United Therapeutics to expand the license to include additional active ingredients. 

New Strong Sell Stocks for August 27th

CVGI, INBK and MNKD have been added to the Zacks Rank #5 (Strong Sell) List on August 27, 2025.

Wall Street issued mixed calls on scPharmaceuticals on Monday after MannKind said it would buy the former in a deal that could total $360 million, or approximately $6.35 per share if all milestones are met.&nbsp;The deal represents a 31% premium to scPharma’s last closing price before the announcement.After the news, Craig-Hallum pulled back its rating on scPharmaceuticals, shifting it from ‘Buy’ to ‘Hold’ and setting a price target of $6.&nbsp;Craig-Hallum noted that shareholders are entitled to receive $5.35 in cash per share, along with the potential to receive up to an additional $1 in cash per share from future milestone payments and the firm expects a majority of the CVR value to be paid out over time.Maxim Group also downgraded scPharmaceuticals to ‘Hold’ from ‘Buy’ following the acquisition agreement under the same terms.By contrast, H.C. Wainwright reiterated a ‘Buy’ rating on MannKind with a $9 price target, saying the acquisition strengthens MannKind’s revenue base and expands its reach into cardiorenal medicine. The firm described the price paid as “very reasonable.”The acquisition gives&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mannkind-corporation-to-acquire-scpharmaceuticals/chssVp5Rd1m">MannKind access to Furoscix</a>, scPharma’s FDA-approved on-body infuser delivering furosemide to treat fluid overload in patients with chronic heart failure and chronic kidney disease.&nbsp;MannKind estimates Furoscix has a total addressable U.S. market of more than $10 billion.scPharma has been expanding its commercial footprint, reporting $27.8 million in net sales for the first half of 2025, a 96% increase year over year, driven by a larger sales force, growth in nephrology, and new integrated delivery network accounts.&nbsp;Its Furoscix ReadyFlow Autoinjector is expected to be filed for FDA approval in the third quarter of 2025, potentially reducing administration time from five hours to less than 10 seconds.The deal is expected to close in the fourth quarter of 2025 pending regulatory approval.&nbsp;At closing, MannKind will also repay and retire scPharma’s credit facility and revenue-sharing obligations to Perceptive, totaling about $81 million if completed by Sept. 30, 2025.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.On Stocktwits, retail sentiment was ‘extremely bullish’ for scPharmaceuticals with ‘extremely high’ message volume, while sentiment for MannKind was ‘bullish’ with ‘high’ message volume.One user remarked that it was unusual to see a smaller company like MannKind buying a larger one, calling the deal “bizarro territory.”<stembedurl>https://stocktwits.com/Kuka/message/626521368</stembedurl>Another user noted that the acquisition would eliminate scPharmaceuticals’ heavy sales and marketing costs, saying they were beginning to appreciate the efficiency gains MannKind could achieve by folding those operations into its own.<stembedurl>https://stocktwits.com/oneyedjacks/message/626485594</stembedurl>While&nbsp;<a href="https://stocktwits.com/symbol/SCPH">scPharmaceuticals’ stock</a> has risen nearly 56% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/MNKD">MannKind’s stock</a> has declined nearly 40% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

MannKind (MNKD) said it would buy scPharmaceuticals (SCPH) in a deal that could total $360 million, or approximately $6.35 per share if all milestones are met. (Photo credit: Getty Images)

MannKind’s $360M scPharma Deal Splits Analysts — Retail Traders Call It ‘Bizarro Territory’ But Stay Bullish

The deal hands MannKind access to scPharma’s Furoscix heart and kidney therapy, a product with a U.S. market potential estimated at over $10 billion.

MannKind Corporation (MNKD) will acquire scPharmaceuticals Inc. (SCPH) in a deal worth up to approximately $360 million, the companies announced on Monday.Under the merger agreement, MannKind will commence a tender offer to acquire all of the outstanding shares of scPharmaceuticals common stock for $5.35 per share in cash at closing, in addition to one contingent value right worth up to $1. The non-tradeable CVR is payable upon achieving certain regulatory and net sales milestones, the companies <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-acquire-scpharmaceuticals-accelerating-revenue-growth">said</a>.The total per-share consideration of up to $6.35 represents a premium of about 31% to SCPH’s closing price on Friday. The transaction is expected to close in the fourth quarter of 2025, subject to necessary approvals.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MNKD">MannKind</a> stayed within ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels. Meanwhile, sentiment around <a href="https://stocktwits.com/symbol/SCPH">SCPH stock</a> jumped from ‘neutral’ to ‘bullish’ territory, accompanied by ‘low’ levels of retail chatter. While shares of MannKind traded 5% lower in the pre-market session, SCPH stock traded 13% higher.scPharmaceuticals currently markets Furoscix, an FDA-approved on-body infuser delivering Furosemide, used to treat fluid overload in adult patients with chronic heart failure (CHF) and chronic kidney disease (CKD). MannKind, which estimates Furoscix has a total addressable market of over $10 billion in the U.S., said that the acquisition will expand its reach into cardiorenal medicine.MannKind also stated that the combined company is expected to have a stronger revenue base with three commercial assets, including Furoscix.While MNKD stock is down by 36% this year, SCPH stock is up by 37%.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/alibaba-stock-sees-retail-chatter-spike-340-ahead-of-earnings/chssFwcRd1Y">Alibaba Stock Sees Retail Chatter Spike 340% Ahead Of Earnings: AI Investment And E-Commerce In Focus</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

MannKind Corporation to Acquire scPharmaceuticals: More Details Inside

MannKind Corporation (MNKD) will acquire scPharmaceuticals Inc. (SCPH) in a deal worth up to approximately $360 million, the companies announced on Monday.

The transaction is expected to close in the fourth quarter of 2025, subject to necessary approvals.

MannKind (MNKD) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

MannKind Corporation (MNKD) said on Wednesday that it has entered into up to $500 million strategic financing agreement with funds managed by Blackstone (BX) after its second-quarter (Q2) revenue missed Wall Street expectations.“The funding will support the expansion of our commercial team in preparation for the anticipated launch of the pediatric indication for Afrezza, if approved, continued pipeline advancement, potential business development opportunities, and general corporate purposes,” MannKind CEO Michael Castagna <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-and-blackstone-announce-500-million-strategic-financing">said</a>.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MNKD">MNKD</a> jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:624/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_06_at_8_42_13_AM_png_d534b5d4d1.webp" alt="MNKD's Sentiment Meter and Message Volume as of 8:24 a.m. ET on Aug. 6, 2025 | Source: Stocktwits" width="624" height="63"><figcaption>MNKD's Sentiment Meter and Message Volume as of 8:24 a.m. ET on Aug. 6, 2025 | Source: Stocktwits</figcaption></figure>Afrezza is an inhaled insulin that starts lowering blood sugars in about 12 minutes for adults living with type 1 or type 2 diabetes. The company is now looking to expand its use to pediatric patients, and a U.S. Food and Drug Administration ruling on the application is expected in early our third quarter.The up to $500 million senior secured credit facility consists of a $75 million initial term loan funded at closing, a $125 million delayed draw term loan (DDTL) available for the next 24 months, subject to customary drawdown conditions, and an additional $300 million uncommitted DDTL available at the mutual agreement of MannKind and Blackstone.MNKD stock is down by 40% this year and by about 24% over the past 12 months.A Stocktwits user opined that the stock is ‘ridiculously undervalued’.<stembedurl>https://stocktwits.com/Keeportrade/message/623911248</stembedurl>Another opined that they were hoping for a partnership announcement from the company over a loan.<stembedurl>https://stocktwits.com/Jaketom/message/623908336</stembedurl>MannKind on Wednesday reported Q2 revenues of $76.5 million, marking a growth of 6% year-on-year (YoY) but below an analyst estimate of $77.82 million. &nbsp;&nbsp;&nbsp;&nbsp;The YoY increase was spurred by an increase in royalties and Afrezza revenue, which offset a decline in collaborations and services revenues and a dip in net revenue for V-Go, the company's wearable insulin delivery device.Adjusted net income came in at $0.05 for the three months through the end of June, in line with estimates.MNKD stock is down by 38% this year and by 24% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/rivian-plans-shut-down-of-illinois-plant-for-three-weeks/chr1UQZRd5b">Rivian Plans Shut Down Of Illinois Plant For Three Weeks, R2 Hopes Sparks Mixed Reactions Among Retail Investors</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

MannKind Announces $500M Financing Agreement With Blackstone After Q2 Revenue Miss: Retail Believes Stock Is ‘Ridiculously Undervalued’

MannKind will receive $75 million in cash at the closing of the agreement. 

MannKind (MNKD) Reports Break-Even Earnings for Q2

MannKind (MNKD) delivered earnings and revenue surprises of -100.00% and -2.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Palantir Technologies Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$5.57
Prev Close	$5.55
Open	$5.51
Dividend Yield	0.00%
50-Day Moving Average	$5.30
Beta	0.95
Avg. Volume	5.63M
PE Ratio	51.14

52-Week High	$7.63
52-Week Low	$3.38
Market Capitalization	$1.72B
EPS (Annual)	$0.0972
Price to Book	-31.11
Revenue Per Employee	$701,484.03
Enterprise Value/EBITDA	N/A

MNKD
Mannkind Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MNKD News

MNKDMannkind Corp